JSPR
NASDAQJasper Therapeutics Inc.
Price$0.48-0.04 (-7.19%)
03:30 PM07:45 PM
News · 26 weeks50+140%
2026-04-192026-10-11
Mix3390d
- SEC Filings13(39%)
- Insider11(33%)
- Other5(15%)
- Analyst2(6%)
- M&A1(3%)
- Offering1(3%)
Latest news
25 items- SECSEC Form 8-K filed by Jasper Therapeutics Inc.8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA NephropathyInitial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026 Announces expansion cohort in patients with FSGS, with first patients anticipated to be dosed in first quarter 2027 REDWOOD CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper" or the "Company"), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that it has completed enrollment of the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104), a first-in-class bifunctional biologic that simultaneously and selectively targets bo
- SECSEC Form S-3 filed by Jasper Therapeutics Inc.S-3 - Jasper Therapeutics, Inc. (0001788028) (Filer)
- ANALYSTWilliam Blair resumed coverage on Jasper TherapeuticsWilliam Blair resumed coverage of Jasper Therapeutics with a rating of Outperform
- SECSEC Form PRE 14A filed by Jasper Therapeutics Inc.PRE 14A - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECSEC Form 8-K filed by Jasper Therapeutics Inc.8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding WarrantsREDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper" or the "Company"), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the "Common Stock"), that were issued in its underwritten public offering on September 18, 2025 (the "Warrants"). The purchase price is $0.324 in cash per Warrant, without interest (the "Offer Purchase Price"). The purpose of the Offer is to reduce the num
- SECSEC Form SC TO-I filed by Jasper Therapeutics Inc.SC TO-I - Jasper Therapeutics, Inc. (0001788028) (Subject)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECAmendment: Jasper Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECSEC Form 8-K filed by Jasper Therapeutics Inc.8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECSEC Form 25-NSE filed by Jasper Therapeutics Inc.25-NSE - Jasper Therapeutics, Inc. (0001788028) (Subject)
- PRJasper Therapeutics Announces Key Regulatory and Clinical AppointmentsLisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper"), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the appointments of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory Affairs and Shiguang Liu, M.D., Ph.D. as Vice President, Clinical Development. "We are excited to have Lisa and Shiguang join us at Jasper following our merger with Kira Pharmaceuticals," said Jee
- PRJasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceREDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper"), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY. H.C. Wainwright 28th Annual Global Investment ConferencePresentation Date/Time: Wednesday, September 16, 2026; 8:00 AM ETPresentation Format: Fireside Chat A live webcast of the fireside chat will be available on the News & Events – Events page of Jasper's Investor Relations website.
- SECSEC Form DEF 14A filed by Jasper Therapeutics Inc.DEF 14A - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECSEC Form 8-K filed by Jasper Therapeutics Inc.8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECSEC Form PRE 14A filed by Jasper Therapeutics Inc.PRE 14A - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECSEC Form 10-Q filed by Jasper Therapeutics Inc.10-Q - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAcquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders Completed a concurrent PIPE financing raising $132 million in gross proceeds REDWOOD CITY, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper"), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended June 30, 2026, and provided a corporate update. "We are excited to unite Jasper Therapeutics and Kira Pharmaceuticals to advance our shared mission o
- ANALYSTPiper Sandler initiated coverage on Jasper Therapeutics with a new price targetPiper Sandler initiated coverage of Jasper Therapeutics with a rating of Overweight and set a new price target of $2.00
- INSIDERSEC Form 4 filed by Director Wiggans Thomas G4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERSEC Form 4 filed by Director Emster Kurt Von4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERSEC Form 4 filed by Director Lucas Svetlana4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERSEC Form 4 filed by Director Crutcher Patrick J4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERSEC Form 4 filed by Director Shizuru Judith Anne4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
JSPR FAQ
7 questionsWhat does Jasper Therapeutics Inc. do?
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.Where does JSPR stock trade?
Jasper Therapeutics Inc. (JSPR) is listed on NASDAQ.What sector and industry is JSPR in?
Jasper Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Jasper Therapeutics Inc. go public?
Jasper Therapeutics Inc. (JSPR) completed its IPO in 2020.What are analysts saying about JSPR?
Jasper Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-10-14.What companies are similar to JSPR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare JSPR side-by-side with any of them on Quantisnow.How can I track JSPR on Quantisnow?
Quantisnow aggregates Jasper Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JSPR to receive live email and push alerts on every new disclosure.